CrossBridge Bio

Executive Summary

CrossBridge Bio is a private biotechnology company headquartered in Cambridge, MA, with operations in Houston, TX, focused on advancing Antibody-Drug Conjugate (ADC) therapeutics. Founded in 2014, the company has developed a proprietary stable dual-linker payload platform designed to overcome key limitations of conventional ADCs, such as off-target toxicity and suboptimal efficacy. By enabling more precise drug release and improved pharmacokinetics, CrossBridge's technology aims to deliver safer and more effective cancer treatments. While the company has not disclosed its total funding or valuation, its platform has the potential to address a broad range of oncology targets. The company's stage is listed as 'Approved,' which may indicate prior validation of its technology or a misclassification; however, as a private entity, it likely operates in the preclinical or early clinical phase. CrossBridge Bio represents an emerging player in the competitive ADC space, with a differentiated approach that could attract partnership interest from larger pharmaceutical companies seeking next-generation ADC technologies.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate IND filing or clinical trial initiation40% success
• Q2 2026Preclinical data presentation at major oncology conference60% success
• Q4 2026Partnership or licensing deal with a larger pharma company30% success